news
AstraZeneca and Novartis set to lose out from US drug prices reforms
A report has suggested that the drug price reforms in the US will affect AstraZeneca and Novartis negatively, but Novo could benefit.
List view / Grid view
Novo Nordisk
news
Global diabetes drug market expected to rise 3.6 percent
A new report predicts that the global diabetes drug market will rise to US$58.4 billion by 2025.
news
Type 2 diabetes treatment approved for children and adolescents
The FDA has approved an injection for use in patients aged 10-17 to treat type 2 diabetes.
news
Application to EMA filed for the approval of oral semaglutide
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
news
Committee demands answers on rising cost of insulin in the US
Letters have been sent to Eli Lilly, Novo Nordisk and Sanofi asking them to explain the rapidly increasing cost of insulin...
news
Pausing evolution makes bioproduction of chemicals affordable and efficient
Circumventing evolution in cell factories can pave the way for commercialising new biobased chemicals to large-scale.
news
Ozempic approved for the treatment of type 2 diabetes
Health Canada has approved Ozempic to improve glycemic control in adults with type 2 diabetes mellitus when metformin is not tolerated or contraindicated...
article
2017 Pipelines: Drugs to watch
The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of more than $900 billion by 2021...
news
New economic data finds Novo Nordisk’s insulin degludec most cost effective diabetic treatment
14 March 2017 | By Niamh Marriott, Junior Editor
A new health economic analysis of two Phase 3b trials has demonstrated that Novo Nordisk's Tresiba is a cost-effective option for diabetes...
article
The top 21… wealthiest pharma companies
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
news
NovoSeven resolved 96.5% of bleeds in haemophilia A or B sufferers
6 December 2016 | By Niamh Louise Marriott, Digital Editor
NovoSeven, a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds demonstrating efficacy with haemophilia...
news
GSK tops list ranking big pharma’s global access to medicine
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries...
news
Post-meal hyperglycaemia has negative impact on diabetic quality of life
4 November 2016 | By Niamh Louise Marriott, Digital Content Producer
New data from a study related to post-meal or postprandial glucose control, show that poor PPG control has a negative impact on diabetics quality of life...
news
Novo Nordisk’s semaglutide reduced major cardiovascular events in 1 in 4 type 2 diabetic adults
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent...
news
Novo Nordisk’s insulin pen receives EU expanded use approval to treat more patients with type 2 diabetes
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The approval is based on data from the phase 3b clinical trial, which examined the efficacy and safety of liraglutide versus placebo as an add-on to existing diabetes medication, to improve glycaemic control...
